Cell proliferation and apoptosis

Current Opinion in Cell Biology

Volumn 11, Issue 6, 1999, Pages 745-752

  Guo, Ming ^a   Hay, Bruce A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; APOPTOSIS; CARCINOGENESIS; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE ACTIVATION; GENE MUTATION; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0032732260     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(99)00046-0     Document Type: Review

References (73)

1. Raff M.C. Social controls on cell survival and cell death. Nature. 356:1992;397-400.
2. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
3. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
4. Harrington E.A., Fanidi A., Evan G.I. Oncogenes and cell death. Curr Opin Genet Dev. 4:1994;120-129.
5. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
6. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 8:1998;49-54.
7. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
8. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 95:1998;5-8.
9. ARF.
10. -/- cells expressing RasV12.
11. -/- cells, are also resistant to apoptosis-inducing stimuli.
12. ARF and p53 function in the same pathway to promote apoptosis.
13. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene, products. Curr Opin Genet Dev, 9:1999;22-30.
14. Tao W., Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 96:1999;6937-6941.
15. Zhang Y., Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell. 3:1999;579-591.
16. Honda R., Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18:1999;22-27.
17. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA. 95:1998;8292-8297.
18. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:1997;649-659.
19. Liao M.J., Yin C., Barlow C., Wynshaw-Boris A., van Dyke T. Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. Mol Cell Biol. 19:1999;3095-3102. The kinase (ataxia telangiectasia mutated) ATM plays an important role in inducing p53 in response to DNA damage. Cells of the choroid plexus (CP) that lack Rb function show increased proliferation and p53-dependent apoptosis. This paper shows that removal of Atm has no effect on p53-dependent apoptosis or CP tumor progression.
20. Gottlieb T.M., Oren M. p53 and apoptosis. Semin Cancer Biol. 8:1998;359-368.
21. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
22. Adams P.D., Kaelin W.G. Jr. Negative control elements of the cell cycle in human tumors. Curr Opin Cell Biol. 10:1998;791-797.
23. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-548.
24. -/- cells of the CP does not accelerate cell growth because E2F-1 is also required for the effective proliferation of these, but not normal cells.
25. Chen Y.N.P., Sharma S.K., Ramsey T.M., Jiang L., Martin M.S., Baker K., Adams P.D., Bair K.W., Kaelin W.G. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA. 96:1999;4325-4329. This paper shows that cell-permeable peptides containing a motif that acts as a docking site for cyclin-CDK2 complexes preferentially induce the death of transformed but not normal cells. Expression of E2F-1 is sufficient to sensitize cells to the apoptosis-inducing activity of the docking site peptides, suggesting that these peptides act by increasing E2F-1 activity.
26. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
27. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 11:1999;255-260.
28. Zou H., Li Y., Liu X., Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 274:1999;11549-11556.
29. Saleh A., Srinivasula S.M., Acharya S., Fishel R., Alnemri E.S. Cytochrome C and dATP-mediated oligomerization of apaf-1 is a prerequisite for procaspase-9 processing. J Biol Chem. 274:1999;17941-17945.
30. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., Lowe S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159. Mouse embryo fibroblasts undergo p53-dependent death in response to c-MYC overexpression. This paper shows that p53-dependent death, but not p53 expression, is suppressed in cells lacking Apaf-1 or caspase-9. Importantly, the surviving cells are able to proliferate in vitro and form tumors in vivo. This argues that the mitochondrial dysfunction leading to the release of cytochrome c is not so great as to preclude cell growth if caspase activation is suppressed. On the basis of these results one might expect to identify Apaf-1 and caspase-9 as tumor suppressors and caspase inhibitors as dominant oncogenes.
31. Fearnhead H.O., McCurrach M.E., O'Neill J., Zhang K., Lowe S.W., Lazebnik Y.A. Oncogene-dependent apoptosis in extracts from drug-resistant cells. Genes Dev. 11:1997;1266-1276.
32. Fearnhead H.O., Rodriguez J., Govek E.E., Guo W.J., Kobayashi R., Hannon G., Lazebnik Y.A. Oncogene-dependent apoptosis is mediated by caspase-9. Proc Natl Acad Sci USA. 95:1998;13664-13669. This paper shows that E1A-dependent apoptosis requires Apaf-1 and caspase-9. This paper, in conjunction with earlier work [31], shows that cells expressing E1A are somehow primed to activate caspase-9. The nature of the priming stimulus is unknown. This paper also shows that cells expressing E1A release are sensitized to release cytochrome c in response to other death stimuli. It is not known if this cytochrome c release occurs as a part of a feedback pathway from active caspase-9 to mitochondria, or if E1A sensitizes mitochondria to cytochrome c release in other ways.
33. White E. Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin Virol. 8:1998;505-513.
34. Juin P., Hueber A.O., Littlewood T., Evan G. c-myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1999;1367-1381. This paper shows that the expression of c-MYC results in an early release of cytochrome c that, although not toxic itself, sensitizes Rat-1 cells to other apoptosis-inducing stimuli. The c-myc-dependent release of cytochrome c is inhibited by IGF-1, which probably acts through the kinase Akt. These observations suggest a model in which the fate of cells expressing c-MYC depends on control of cytochrome c release and the extent of activation of other death pathways.
35. Hueber A.O., Zornig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309.
36. Kennedy S.G., Kandel E.S., Cross T.K., Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol. 19:1999;5800-5810.
37. Johnson D.G., Walker C.L. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 39:1999;295-312.
38. Polyak K., Waldman T., He T.C., Kinzler K.W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1996;1945-1952.
39. Gorospe M., Cirielli C., Wang X., Seth P., Capogrossi M.C., Holbrook N.J. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene. 14:1997;929-935.
40. Poluha W., Poluha D.K., Chang B.C., Crosbie N.E., Schonhoff C.M., Kilpatrick D.L., Ross A.H. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol. 16:1996;1335-1341.
41. Wang J., Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science. 273:1996;359-361.
42. CDC2 activation. This leads to a loss of Taxol-dependent cell death.
43. Kip1. The cleaved products have a decreased affinity for cyclin-CDK complexes and p21 exits the nucleus.
44. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18:1999;1223-1234.
45. Fujio Y., Guo K., Mano T., Mitsuuchi Y., Testa J.R., Walsh K. Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol Cell Biol. 19:1999;5073-5082.
46. Xaus J., Cardo M., Valledor A.F., Soler C., Lloberas J., Celada A. Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity. 11:1999;103-113.
47. Suzuki A., Tsutomi Y., Akahane K., Araki T., Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene. 17:1998;931-939.
48. Shi L., Nishioka W.K., Th'ng J., Bradbury E.M., Litchfield D.W., Greenberg A.H. Premature p34cdc2 activation required for apoptosis. Science. 263:1994;1143-1145.
49. Chen G., Shi L., Litchfield D.W., Greenberg A.H. Rescue from granzyme B-induced apoptosis by Wee1 kinase. J Exp Med. 181:1995;2295-2300.
50. Meikrantz W., Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem. 271:1996;10205-10209.
51. Shi L., Chen G., He D., Bosc D.G., Litchfield D.W., Greenberg A.H. Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J Immunol. 157:1996;2381-2385.
52. Yao S.L., McKenna K.A., Sharkis S.J., Bedi A. Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1β -converting enzyme-related proteases. Cancer Res. 56:1996;4551-4555.
53. •,57] for alternative views on cyclin partners.
54. McPherson J.P., Goldenberg G.J. Induction of apoptosis by deregulated expression of DNA topoisomerase IIα Cancer Res. 58:1998;4519-4524.
55. Park D.S., Morris E.J., Padmanabhan J., Shelanski M.L., Geller H.M., Greene L.A. Cyclin-dependent kinases participate in death of neurons evoked by DNA-damaging agents. J Cell Biol. 143:1998;457-467.
56. Zhou B.B., Li H., Yuan J., Kirschner M.W. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci USA. 95:1998;6785-6790. Fas-induced death of Jurkat cells requires CDC2 and CDK2 [52]. This paper describes mechanisms by which CDK upregulation occurs. CDK induction is associated with a rapid shutoff of protein synthesis, cleavage of wee1, an inhibitory kinase of CDC2 and CDK2, and cleavage of CDC27, a component of the anaphase-promoting complex, which degrades cyclins. Thus inhibition of CDK activity is overcome and cyclin levels are stabilized. Despite CDC2 and CDK2 activation, other events associated with cell cycle progression do not occur.
57. Hakem A., Sasaki T., Kozieradzki I., Penninger J.M. The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. J Exp Med. 189:1999;957-968.
58. Rudolph B., Saffrich R., Zwicker J., Henglein B., Muller R., Ansorge W., Eilers M. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A., but not apoptosis. EMBO J. 15:1996;3065-3076.
59. Gervais J.L., Seth P., Zhang H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem. 273:1998;19207-19212.
60. Zhang Y., Fujita N., Tsuruo T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene. 18:1999;1131-1138.
61. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:1998;3247-3259.
62. Luque I., Gelinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol. 8:1997;103-111.
63. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:1997;917-921.
64. 2/M in synchronized cell populations.
65. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 152:1998;43-49.
66. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:1998;5315-5320. Survivin is shown to inhibit apoptosis in response to a number of different stimuli and to bind to caspase-3 and caspase-7. These studies do not address whether the carboxy-terminal coiled-coil domain is required for anti-apoptotic function. Survivin is upregulated in a number of transformed cell lines.
67. 2/M. These observations suggest that Survivin may be required during this stage to inhibit apoptosis-inducing caspase activity.
68. Ambrosini G., Adida C., Sirugo G., Altieri D.C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 273:1998;11177-11182.
69. Uren A.G., Beilharz T., O'Connell M.J., Bugg S.J., van Driel R., Vaux D.L., Lithgow T. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc Natl Acad Sci USA. 96:1999;10170-10175. The yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe both encode IAP-like proteins with significant homology to Survivin in the BIR domain. Evidence is presented that these genes are required for aspects of cell division.
70. Fraser A.G., James C., Evan G.I., Hengartner M.O. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol. 9:1999;292-301. Several Caenorhabditis elegans IAP homologs were characterized. There is no evidence that either protein plays a role in regulating cell death. One of the proteins, BIR-1, is required for cytokinesis.
71. Wang S.L., Hawkins C.J., Yoo S.J., Muller H.A., Hay B.A. The Drosophila caspase inhibitor DIAP1 is essential for cell survival and is negatively regulated by HID. Cell. 98:1999;453-463. IAP function is shown to be required for cell survival, and proteins that promote cell death by disrupting IAP-caspase interactions are identified.
72. ••].
73. ••]. Importantly, both papers show that although myc-induced proliferation requires cyclin D, myc-induced apoptosis does not. Thus, myc-induced proliferation and apoptosis are separable.